Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration.

Author(s): Power WJ, Benedict-Smith A, Hillery M, Brady K, Collum LM

Affiliation(s): Professorial Unit, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.

Publication date & source: 1991-11, Br J Ophthalmol., 75(11):649-51.

Publication type: Clinical Trial; Comparative Study; Randomized Controlled Trial

The results of a randomised double-blind clinical trial of 0.1% bromovinyldeoxyuridine (BVDU) and 1% trifluorothymidine (TFT) in 60 patients with corneal dendritic ulceration are presented. There was no significant difference between BVDU and TFT in terms of numbers of ulcers healed (p = 0.61), mean healing time (p = 0.065), and cumulative healing rate (p = 0.058). No serious side effects were observed, though transient stinging was recorded in five patients receiving TFT and in three patients receiving BVDU. One patient in the group treated with TFT developed a punctate epitheliopathy.